Claims for Patent: 7,799,777

Summary for Patent: 7,799,777

Title:	Salts of potassium ATP channel openers and uses thereof
Abstract:	Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
Inventor(s):	Neil M. Cowen, Khaled A. Yamout
Assignee:	Essentialis Inc
Application Number:	US11/614,044
Patent Claims:	1. Crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt having characteristic peaks in a XRPD pattern substantially as shown in FIG. 13( b). 2. The crystalline form B of claim 1, wherein said characteristic peaks comprise two-theta peaks (Cu Kα, 40 kV, 40 mA) at approximately 10.3, 18.3, 20.6, and 26.3 degrees. 3. The crystalline form B of claim 1, wherein said characteristic peaks comprise two-theta peaks (Cu Kα, 40 kV, 40 mA) at approximately 8.9, 12.0, 24.1, 24.5, 27.1, and 28.9 degrees. 4. Crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt having an NMR spectrum substantially as shown in FIG. 17( b). 5. The crystalline form B of claim 4 having characteristic chemical shifts in an NMR spectrum (DMSO-d6 solvent) at approximately 2.05, 3.10, 3.40, and 3.85 ppm. 6. The crystalline form B of claim 4 having characteristic chemical shifts in an NMR spectrum (DMSO-d6 solvent) at approximately 7.10, 7.30, and 7.50 ppm. 7. Crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt having characteristic infrared absorbances at 3256, 2174, 2890, 1605, 1463, and 1235 cm−1. 8. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from diazoxide and choline hydroxide, comprising: a) suspending diazoxide in tetrahydrofuran (THF) or 2-methyltetrahydrofuran (2-MeTHF); b) heating the diazoxide containing suspension; c) adding a choline hydroxide solution to the diazoxide containing suspension; and d) removing the solvent to form crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt; wherein if diazoxide is suspended in THF, diazoxide is suspended in THF at a ratio of about 1 g diazoxide per 3 mL THF to about 1 g diazoxide per 8 mL THF, and if diazoxide is suspended in 2-MeTHF, diazoxide and 2-MeTHF are present at a ratio of about 1 g diazoxide per 2 mL 2-MeTHF to about 1g diazoxide per 8 mL 2-MeTHF. 9. The process of claim 8, wherein diazoxide is suspended in THF. 10. The process of claim 8, wherein diazoxide is suspended in 2-MeTHF. 11. The process of claim 8, wherein said choline hydroxide solution comprises choline hydroxide, dissolved in methanol (MeOH). 12. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from diazoxide and choline hydroxide, comprising: a) suspending diazoxide in tetrahydrofuran (THF), 2-methyltetrahydrofuran (2-MeTHF), acetonitrile (MeCN), or methyl ethyl ketone (MEK); b) adding a choline hydroxide solution to the diazoxide containing suspension; c) heating the diazoxide containing suspension; d) adding methyl tert butyl ether (MTBE) as a co-solvent to the suspension to form a precipitate; e) harvesting the precipitate to provide crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt; wherein if diazoxide is suspended in THF, 2-MeTHF, or MeCN, diazoxide is suspended in THF, 2-MeTHF, or MeCN at a ratio of about 1 g diazoxide per 1 mL THF, 2-MeTHF, or MeCN to about 1 g diazoxide per 8 mL THF, 2-MeTHF, or MeCN, and if diazoxide is suspended in MEK, diazoxide is suspended in MEK at a ratio of about 1 g diazoxide per 4 mL MEK. 13. The process of claim 12, wherein diazoxide is suspended in THF. 14. The process of claim 12, wherein diazoxide is suspended in 2-MeTHF. 15. The process of claim 12, wherein diazoxide is suspended in MeCN. 16. The process Of claim 12, wherein diazoxide is suspended in MEK. 17. The process of claim 12, wherein said choline hydroxide solution comprises choline hydroxide dissolved in methanol (MeOH). 18. The process of claim 12, wherein the amount of co-solvent added is in a ratio to the amount of THF, 2-MeTHF, or MeCN of about 1:1-20 (solvent:co-solvent). 19. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt comprising: a) suspending crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt in acetonitrile (MeCN) or isoamyl alcohol (i-AmOH); b) heating the salt containing suspension; c) cooling the salt containing suspension to form a precipitate; and d) harvesting the precipitate to provide crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt substantially free of form A. 20. The process of claim 19, wherein said cooling comprises fast cooling. 21. The process of claim 19, wherein said cooling comprises slow cooling. 22. The process of claim 19, wherein the salt is suspended in MeCN. 23. The process of claim 19, wherein the salt is suspended in i-AmOH. 24. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt comprising: a) suspending crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt in isopropyl alcohol (IPA), tert-amyl alcohol (t-AmOH), or iso-butanol (i-BuOH); b) heating the salt containing suspension; c) slow cooling the suspension to room temperature to form a precipitate; and d) harvesting the precipitate to provide crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt substantially free of form A. 25. The process of claim 19, wherein the salt is suspended in IPA. 26. The process of claim 19, wherein the salt is suspended in t-AmOH. 27. The process of claim 19, wherein the salt is suspended in i-BuOH. 28. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt comprising: a) suspending crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt in methanol (MeOH), or ethanol (EtOH); b) adding methyl tert butyl ether (MTBE), ethyl acetate (EtOAc), isopropyl acetate (IPAc), tetrahydrofuran (THF), c-hexane, heptane, toluene, dichloromethane (CH2Cl2), or dioxane as a co-solvent to the suspension; c) heating the salt containing suspension; d) fast cooling the heated suspension to form a precipitate; and e) harvesting the precipitate to provide crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt substantially free of form A; wherein if the suspension is formed in MeOH, the co-solvent is selected from the group consisting of MTBE, EtOAc, IPAc, toluene, and dioxane. 29. The process of claim 28, wherein the salt is suspended in MeOH. 30. The process of claim 28, wherein the salt is suspended in EtOH. 31. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt comprising: a) suspending crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt in methanol isopropanol (IPA) or acetonitrile (MeCN); b) adding methyl tert butyl ether (MTBE), ethyl acetate (EtOAc), isopropyl acetate (IPAc), tetrahydrofuran (THF), c-hexane, heptane, toluene, dichloromethane (CH2Cl2), or dioxane as a co-solvent to the suspension; c) heating the salt containing suspension; d) slow cooling the heated suspension to form a precipitate; and e) harvesting the precipitate to provide crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt substantially free of form A. 32. The process of claim 31, wherein the salt is suspended in IPA. 33. The process of claim 19, wherein the salt is suspended in MeCN. 34. A process for producing crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt from crystalline form A or a mixture of crystalline forms A and B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt comprising slurrying said crystalline form A or a mixture of crystalline forms A and B in a solvent to generate a slurry comprising crystalline form B substantially free of crystalline form A. 35. A pharmaceutical composition comprising an effective amount of the crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt of one of claims 1-7. 36. A pharmaceutical composition comprising an effective amount of a crystalline form B of 7-chloro-3-methyl-2H-1,2,4-benzothiadiazine dioxide:2-hydroxy-N,N,N-trimethyl ethanaminium (1:1) salt generated by the process of one of claims 8 to 34.